Can Fite (Israel) Performance

CANF -- Israel Stock  

ILS 98.00  6.10  5.86%

The firm shows Beta (market volatility) of -0.9347 which signifies that Even though it is essential to pay attention to Can Fite BioPharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Can Fite BioPharma Ltd exposes twenty-one different technical indicators which can help you to evaluate its performance. Can Fite BioPharma has expected return of -3.0608%. Please be advised to confirm Can Fite BioPharma Standard Deviation, Information Ratio, Treynor Ratio, as well as the relationship between Variance and Jensen Alpha to decide if Can Fite BioPharma past performance will be repeated at some point in the near future.
0

Risk-Adjusted Performance

Over the last 30 days Can Fite BioPharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in May 2019. The current disturbance may also be a sign of long term up-swing for the company investors.
Quick Ratio1.26
Fifty Two Week Low109.10
Target High Price6.00
Fifty Two Week High300.00
Target Low Price6.00
Horizon     30 Days    Login   to change

Can Fite BioPharma Relative Risk vs. Return Landscape

If you would invest  21,450  in Can Fite BioPharma Ltd on March 21, 2019 and sell it today you would lose (11,650)  from holding Can Fite BioPharma Ltd or give up 54.31% of portfolio value over 30 days. Can Fite BioPharma Ltd is generating negative expected returns and assumes 8.7735% volatility on return distribution over the 30 days horizon. Simply put, 78% of equities are less volatile than Can Fite and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, Can Fite is expected to under-perform the market. In addition to that, the company is 15.31 times more volatile than its market benchmark. It trades about -0.35 of its total potential returns per unit of risk. The DOW is currently generating roughly 0.12 per unit of volatility.

Can Fite Market Risk Analysis

Sharpe Ratio = -0.3489
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsCANF

Can Fite Relative Performance Indicators

Estimated Market Risk
 8.77
  actual daily
 
 78 %
of total potential
 
78
Expected Return
 -3.06
  actual daily
 
 0 %
of total potential
 
0
Risk-Adjusted Return
 -0.35
  actual daily
 
 0 %
of total potential
 
0
Based on monthly moving average Can Fite is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Can Fite by adding it to a well-diversified portfolio.

Can Fite Alerts

Equity Alerts and Improvement Suggestions

Can Fite BioPharma generates negative expected return over the last 30 days
Can Fite BioPharma has high historical volatility and very poor performance
The company reported revenue of 3.82M. Net Loss for the year was (6.57M) with profit before overhead, payroll, taxes, and interest of 3.82M.
CAN-FITE BIOPHARMA has accumulated about 3.89M in cash with (4.16M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check also Trending Equities. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Search macroaxis.com